These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 8232810)
1. Comparison of intrathecal administration of urokinase and tissue plasminogen activator on subarachnoid clot and chronic vasospasm in a primate model. Hariton GB; Findlay JM; Weir BK; Kasuya H; Grace MG; Mielke BW Neurosurgery; 1993 Oct; 33(4):691-6; discussion 696-7. PubMed ID: 8232810 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of intrathecal thrombolytic therapy in a primate model of cerebral vasospasm. Findlay JM; Weir BK; Gordon P; Grace M; Baughman R Neurosurgery; 1989 Apr; 24(4):491-8. PubMed ID: 2496328 [TBL] [Abstract][Full Text] [Related]
3. Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in a primate model of SAH. Findlay JM; Weir BK; Steinke D; Tanabe T; Gordon P; Grace M J Neurosurg; 1988 Nov; 69(5):723-35. PubMed ID: 3141595 [TBL] [Abstract][Full Text] [Related]
4. The effect of timing of intrathecal fibrinolytic therapy on cerebral vasospasm in a primate model of subarachnoid hemorrhage. Findlay JM; Weir BK; Kanamaru K; Grace M; Baughman R Neurosurgery; 1990 Feb; 26(2):201-6. PubMed ID: 2106630 [TBL] [Abstract][Full Text] [Related]
5. Vasospasm prevention with postoperative intrathecal thrombolytic therapy: a retrospective comparison of urokinase, tissue plasminogen activator, and cisternal drainage alone. Usui M; Saito N; Hoya K; Todo T Neurosurgery; 1994 Feb; 34(2):235-44; discussion 244-5. PubMed ID: 8177383 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage. Seifert V; Eisert WG; Stolke D; Goetz C Neurosurgery; 1989 Oct; 25(4):590-8. PubMed ID: 2507953 [TBL] [Abstract][Full Text] [Related]
7. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Findlay JM; Kassell NF; Weir BK; Haley EC; Kongable G; Germanson T; Truskowski L; Alves WM; Holness RO; Knuckey NW Neurosurgery; 1995 Jul; 37(1):168-76; discussion 177-8. PubMed ID: 8587685 [TBL] [Abstract][Full Text] [Related]
8. Intrathecal fibrinolytic therapy after subarachnoid hemorrhage: dosage study in a primate model and review of the literature. Findlay JM; Weir BK; Kanamaru K; Grace M; Gordon P; Baughman R; Howarth A Can J Neurol Sci; 1989 Feb; 16(1):28-40. PubMed ID: 2493974 [TBL] [Abstract][Full Text] [Related]
9. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs. Kajimoto Y; Ohta T; Kuroiwa T Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298 [TBL] [Abstract][Full Text] [Related]
10. The effect of tissue plasminogen activator (t-PA) on cerebral vasospasm in canine subarachnoid hemorrhage. Chung WY; Lee LS Zhonghua Yi Xue Za Zhi (Taipei); 1993 Nov; 52(5):298-306. PubMed ID: 8299025 [TBL] [Abstract][Full Text] [Related]
11. Effects of unilateral intrathecal administrations of low dose tissue-type plasminogen activator on clot lysis, vasospasm and brain phospholipid hydroperoxidation in a primate model of bilateral subarachnoid hemorrhage. Suzuki H; Kanamaru K; Kuroki M; Sun H; Waga S; Miyazawa T Neurol Res; 1998 Oct; 20(7):625-31. PubMed ID: 9785591 [TBL] [Abstract][Full Text] [Related]
12. Intrathecal nimodipine therapy in a primate model of chronic cerebral vasospasm. Lewis PJ; Weir BK; Nosko MG; Tanabe T; Grace MG Neurosurgery; 1988 Mar; 22(3):492-500. PubMed ID: 3362315 [TBL] [Abstract][Full Text] [Related]
13. Effect of BQ-123 and tissue plasminogen activator on vasospasm after subarachnoid hemorrhage in monkeys. Kim CJ; Bassiouny M; Macdonald RL; Weir B; Johns LM Stroke; 1996 Sep; 27(9):1629-33. PubMed ID: 8784140 [TBL] [Abstract][Full Text] [Related]
14. [Preliminary clinical trial of intrathecal rt-PA (TD-2061) for the prevention of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage]. Sasaki T; Ohta T; Kikuch H; Takakura K; Usui M; Kondoh A; Tanabe H; Nakamura J; Yamada K No To Shinkei; 1992 Nov; 44(11):1001-8. PubMed ID: 1296711 [TBL] [Abstract][Full Text] [Related]
15. A phase II clinical trial of recombinant human tissue-type plasminogen activator against cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Sasaki T; Ohta T; Kikuchi H; Takakura K; Usui M; Ohnishi H; Kondo A; Tanabe H; Nakamura J; Yamada K Neurosurgery; 1994 Oct; 35(4):597-604; discussion 604-5. PubMed ID: 7808602 [TBL] [Abstract][Full Text] [Related]
16. Prospective, randomized, double-blind trial of BQ-123 and bosentan for prevention of vasospasm following subarachnoid hemorrhage in monkeys. Hino A; Weir BK; Macdonald RL; Thisted RA; Kim CJ; Johns LM J Neurosurg; 1995 Sep; 83(3):503-9. PubMed ID: 7666230 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage. Zabramski JM; Spetzler RF; Lee KS; Papadopoulos SM; Bovill E; Zimmerman RS; Bederson JB J Neurosurg; 1991 Aug; 75(2):189-96. PubMed ID: 1906534 [TBL] [Abstract][Full Text] [Related]
18. Effect of clot removal at 24 hours on chronic vasospasm after SAH in the primate model. Nosko M; Weir BK; Lunt A; Grace M; Allen P; Mielke B J Neurosurg; 1987 Mar; 66(3):416-22. PubMed ID: 3819837 [TBL] [Abstract][Full Text] [Related]
19. Diffusion-, T2-, and perfusion-weighted nuclear magnetic resonance imaging of middle cerebral artery embolic stroke and recombinant tissue plasminogen activator intervention in the rat. Jiang Q; Zhang RL; Zhang ZG; Ewing JR; Divine GW; Chopp M J Cereb Blood Flow Metab; 1998 Jul; 18(7):758-67. PubMed ID: 9663506 [TBL] [Abstract][Full Text] [Related]